FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

| OMB APPROVAL | | | | | | | | | |
|--------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average | burden | | | | | | | | |
| hours nor resnonse | . 0.5 | | | | | | | | |

| | | | | | | | ,,, 00(| (11) 01 111 | C IIIVCOLI | iiciii (| Sompany Act | 01 10-10 | | | | | | | |
|--|--------------------|--|----------|------------|--|--|-------------------------------------|--|---|---------------|---|-------------------------------|---|---|---|--|--|--------|--|
| Name and Address of Reporting Person* Morrison Briggs | | | | | | 2. Issuer Name and Ticker or Trading Symbol Syndax Pharmaceuticals Inc [SNDX] | | | | | | | (Ch | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | |
| MOLLISOII DII 882 | | | | | <u> </u> | | | | | | | | | X Direct | or | | 10% Ow | ner | |
| (Last) | (First) (Middle) | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 07/10/2023 | | | | | | | | Office below | r (give title) | | Other (s below) | pecify | |
| C/O SYNDAX PHARMACEUTICALS, INC. | | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | |
| 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3 | | | | 3 | | | | | | | | | X Form filed by One Reporting Person | | | | | | |
| (Street) WALTHAM MA 02451 | | | | | Form filed by More than One Reporting Person | | | | | | | | | | | | | | |
| | WALITIAWI WA 02451 | | | - Ru | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | | | | | |
| (City) (State) (Zip) | | | | | | | | | | | | | | | | | | | |
| | | | | | X | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | | | |
| | | Tab | le I - 1 | Non-Deriv | vative | Sec | curit | ies A | cquire | d, D | isposed o | of, or B | eneficial | ly Owne | d | | | | |
| 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye | | | | /Year) | Execution Date, | | Transaction Disposed O Code (Instr. | | es Acquired (A) or Of (D) (Instr. 3, 4 and | | | ties cially I Following | Form: | Direct of Indirect Istr. 4) | 7. Nature of Indirect Beneficial Ownership | | | | |
| | | | | | | | Code | v | Amount | (A) or (D) | Price | Transa | eported ransaction(s) nstr. 3 and 4) | | | (Instr. 4) | | | |
| Common Stock 07/10/202 | | | | 023 | 23 | | | M | | 52,855 | Α | \$8.77 | 7 | 0,691 | D | | | | |
| Common Stock 07/10/202 | | | | 023 | 23 | | S ⁽¹⁾ | | 52,855 | D | \$20.3967 | 7(2) 1 | 7,836 | D | | | | | |
| | | Т | able | | | | | | | | posed of | | | Owned | | | | | |
| | | | | (e.g., p | | calls | _ | | | | , converti | | | | 1 | | | | |
| Derivative Conversion Date | | 3. Transaction Date (Month/Day/Year) | if any | tion Date, | 4. Transac Code (li 8) | | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | ate | 7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | ve derivativ Securitie | e s ally g | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | Code | v | (A) | (D) | Date Exercis | sable | Expiration Date | Title | Amount or Number of Shares | | | | | | |
| Stock | | | | | | | Н | | | | | | | | | | | | |

Explanation of Responses:

1. Following the sales reported in this Form 4, the Reporting Person has a total of 601,143 options to purchase shares of common stock that are vested and immediately exercisable and a total of 258,729 options to purchase shares of common stock that have not yet vested.

(3)

02/06/2027

52,855

- 2. The sale prices ranged from \$20.11 to \$20.71.
- 3. This option is fully vested.

Remarks:

Options (Right to

buy)

/s/ Michael A. Metzger, Attorney-in-fact

07/11/2023

0.00

** Signature of Reporting Person

52,855

Stock

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

07/10/2023

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.